Role of vortioxetine in the treatment of neuropathic pain

Montero, A. Alcántara; Vasconcelos, S.R. Pacheco de

doi:10.1016/j.redare.2022.09.003

Cited by 5 publications

(13 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, based on previous reports presenting the therapeutic potential of vortioxetine for acute [ 12 , 13 ], inflammatory [ 11 ] and neuropathic pain [ 7 , 14 ], the potential efficacy of this drug against diabetes-induced hyperalgesia and allodynia responses was investigated in rats. Further mechanistic studies were conducted in order to elucidate the promising contributions of the catecholaminergic and cholinergic systems to the antihyperalgesic and antiallodynic activities of vortioxetine.…”

Section: Discussionmentioning

confidence: 99%

“…Considering that the pharmacological action of vortioxetine is mediated by multiple neurotransmitter systems, it can be thought that this drug may have various therapeutic effects on the central nervous system. For example, a number of studies in the literature suggest that this drug may also be effective for treating both acute and chronic pain [ 7 , 11 , 12 , 13 , 14 ]. The beneficial effects of this drug have been shown in some neuropathic pain models, including reserpine-induced fibromyalgia [ 15 ], chronic constriction injury [ 16 ], chronic neuropathic orofacial pain [ 7 , 17 ] and oxaliplatin-induced neuropathy [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain

et al. 2023

View full text Add to dashboard Cite

The therapeutic potential of vortioxetine on mechanical hyperalgesia/allodynia was investigated in rats with streptozotocin-induced diabetes, and its possible mechanism of action was elucidated in this study. The obtained findings demonstrated that subacute vortioxetine treatment (5 and 10 mg/kg for 2 weeks) increased the reduced paw-withdrawal thresholds of diabetic rats both in the Randall–Selitto and Dynamic plantar tests. Moreover, the falling latencies of animals did not change in the Rota-rod assessments. These results suggest that vortioxetine administration significantly improved diabetes-induced hyperalgesia and allodynia responses in the rats without affecting their motor coordination. The vortioxetine (5 mg/kg)-induced antihyperalgesic and antiallodynic effects were reversed by AMPT, yohimbine, ICI 118,551, sulpiride and atropine pre-treatments, suggesting the involvement of the catecholaminergic system, α2- and β2-adrenoceptors, D2/3 dopaminergic receptors and cholinergic muscarinic receptors in the exhibited pharmacological activity, respectively. Moreover, the data from the immunohistochemical studies indicated that the inhibition of c-Fos overexpression in dorsal horn neurons also mediates the beneficial effect of this drug. Vortioxetine induced no difference in plasma glucose levels in diabetic rats. If clinical studies confirm these findings, the concomitant beneficial effect of vortioxetine on mood disorders and its neutral activity profile on glycemic control may make it an alternative drug for the treatment of neuropathic pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain

et al. 2023

View full text Add to dashboard Cite

show abstract

“…CP constitutes a stress state that is a critical factor in determining depression [ 2 ]. Thus, depression is considered one of the most frequent psychiatric complications in patients with CP [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Depression in patients with CP is associated with a reduced pain threshold, increased pain perception, greater functional limitations, and worse analgesic response [ 3 ]. Likewise, the presence of pain reduces the chance of recovery from depression and is related to more intense symptoms in these patients [ 8 ], including impaired sleep, enhanced anxiety, and impaired cognition [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…This is believed to be the principal mechanism underlying the antidepressant effects of vortioxetine and numerous other antidepressants [ 38 ]. Evidence suggests that serotonergic pathways are involved in the inhibitory control of pain, although the effect of 5HT on pain modulation in the spinal cord may be inhibitory or facilitatory, depending on which receptor subtypes are preferentially activated [ 3 ]. Vortiotexine also regulates multiple 5-HT receptor subtypes related to pain transmission at the same time: it exerts agonist action at 5-HT1A receptors (Ki = 15 nM), hastening its desensitization and making 5-HT release occur faster [ 39 ]; partial agonist action at 5-HT1B receptors (Ki = 33 nM) and antagonist action at 5-HT1D (Ki = 54 nM) and 5HT7 (Ki = 19 nM) receptors, inhibiting the serotonin release brake [ 39 ]; and antagonist action at 5HT3 (Ki = 3.7 nM) receptor, involved in 5HT-induced hyperalgesia [ 39 , 40 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder Associated with Chronic Pain: An Observational Study in a Spanish Population

Folch Ibáñez,

Vargas Domingo,

Coma Alemany

et al. 2024

Pain Ther

View full text Add to dashboard Cite

Introduction Chronic pain (CP) and depression/anxiety often coexist, worsening each other's symptoms. Treating this comorbidity is challenging. Tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors are the first-line treatment options for this comorbidity, although sometimes they are not effective and/or well tolerated by patients, and there is little clinical evidence that selective serotonin reuptake inhibitors are useful for controlling CP. The antidepressant vortioxetine, with a multimodal mechanism that may help reduce pain, has proven clinical efficacy in patients with major depressive disorder (MDD). This study investigated vortioxetine's effectiveness for MDD and CP in clinical practice. Methods This was a 3-month, multicenter, prospective, open-label, non-interventional pharmacoepidemiologic study. Patients ( n = 64) with MDD (9-item Patient Health Questionnaire [PHQ-9] score ≥ 15) and CP (visual analogue scale [VAS] score ≥ 4) were treated with vortioxetine for 3 months (initiated with 10 mg/day, with flexible dosing thereafter [5–20 mg/day]). VAS, Clinical Global Impression (CGI), and Patient Global Impression (PGI) scales were used at baseline and at 1 and 3 months. Brief Pain Inventory (BPI), PHQ-9 scale, and Satisfaction with Medicines Questionnaire (SATMED-Q) were used at baseline and at 3 months. Adverse Events (AEs) were recorded. Descriptive statistics, chi-square tests, and Student's t -tests were used for paired data. Results MDD patients showed a statistically significant improvement in VAS from baseline (mean [standard deviation (SD)]: 7.42 [0.69]) to 1 month (mean [SD]: 6.1 [0.81], P < 0.001) and 3 months (mean [SD]: 5.09 [1.26], P < 0.0001). Similarly, BPI and PHQ-9 scores showed significant improvement from baseline (mean [SD]: 6.20 [0.80] and 16.63 [1.47], respectively) to 3 months (mean [SD]: 4.73 [0.98] and 7.30 [2.60], P < 0.0001, respectively). Patients showed clinical improvement with CGI and PGI scales and reported being satisfied with the treatment in the SATMED-Q. A few mild EAs were registered. Conclusion Vortioxetine can relieve depressive and pain symptoms, with a good safety profile, in patients with MDD and CP. Supplementary Information The online version contains supplementary material available at 10.1007/s40122-024-00597-3.

show abstract

Correlation analysis between the early diagnosis and severity of neuropathic pain and the activation level of NLRP3 inflammasome: A retrospective study

Wang,

Zhou,

Zhou

2024

Medicine

View full text Add to dashboard Cite

To investigate the correlation between neuropathic pain’s early diagnosis, severity, and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation, we retrospectively evaluated 50 patients with neuropathic pain and 50 healthy individuals. Activation of the NLRP3 inflammasome was measured in blood samples, as well as pain levels and clinical markers. Neuropathic pain patients exhibited elevated NLRP3 inflammasome activation. Pain intensity positively correlated with activation. Correlation was also observed with inflammatory markers and pain-related biomarkers. NLRP3 inflammasome demonstrated high diagnostic sensitivity. In conclusion, NLRP3 inflammasome activation influences neuropathic pain initiation and progression. Measuring activation levels may serve as an early diagnostic indicator and severity gauge for neuropathic pain.

show abstract

Role of vortioxetine in the treatment of neuropathic pain

Cited by 5 publications

References 44 publications

Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain

Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder Associated with Chronic Pain: An Observational Study in a Spanish Population

Correlation analysis between the early diagnosis and severity of neuropathic pain and the activation level of NLRP3 inflammasome: A retrospective study

Contact Info

Product

Resources

About